• 1
    Clavien PA, Petrowsky H, DeOliveira ML, Graf R. Strategies for safer liver surgery and partial liver transplantation. N Engl J Med 2007; 356: 1545-1559.
  • 2
    Starzl TE, Putnam CW, Groth CG, Corman JL, Taubman J. Alopecia, ascites, and incomplete regeneration after 85 to 90 per cent liver resection. Am J Surg 1975; 129: 587-590.
  • 3
    Dahm F, Georgiev P, Clavien PA. Small-for-size syndrome after partial liver transplantation: definition, mechanisms of disease and clinical implications. Am J Transplant 2005; 5: 2605-2610.
  • 4
    Balzan S, Belghiti J, Farges O, Ogata S, Sauvanet A, Delefosse D, et al. The “50-50 criteria” on postoperative day 5: an accurate predictor of liver failure and death after hepatectomy. Ann Surg 2005; 242: 824-828.
  • 5
    Paugam-Burtz C, Janny S, Delefosse D, Dahmani S, Dondero F, Mantz J, et al. Prospective validation of the “fifty-fifty” criteria as an early and accurate predictor of death after liver resection in intensive care unit patients. Ann Surg 2009; 249: 124-128.
  • 6
    Schindl MJ, Redhead DN, Fearon KC, Garden OJ, Wigmore SJ. The value of residual liver volume as a predictor of hepatic dysfunction and infection after major liver resection. Gut 2005; 54: 289-296.
  • 7
    Breitenstein S, Apestegui C, Petrowsky H, Clavien PA. “State of the art” in liver resection and living donor liver transplantation: a worldwide survey of 100 liver centers. World J Surg 2009; 33: 797-803.
  • 8
    Ben-Haim M, Emre S, Fishbein TM, Sheiner PA, Bodian CA, Kim-Schluger L, et al. Critical graft size in adult-to-adult living donor liver transplantation: impact of the recipient's disease. Liver Transpl 2001; 7: 948-953.
  • 9
    Shoup M, Gonen M, D'Angelica M, Jarnagin WR, DeMatteo RP, Schwartz LH, et al. Volumetric analysis predicts hepatic dysfunction in patients undergoing major liver resection. J Gastrointest Surg 2003; 7: 325-330.
  • 10
    Vauthey JN, Chaoui A, Do KA, Bilimoria MM, Fenstermacher MJ, Charnsangavej C, et al. Standardized measurement of the future liver remnant prior to extended liver resection: methodology and clinical associations. Surgery 2000; 127: 512-519.
  • 11
    Shirabe K, Shimada M, Gion T, Hasegawa H, Takenaka K, Utsunomiya T, et al. Postoperative liver failure after major hepatic resection for hepatocellular carcinoma in the modern era with special reference to remnant liver volume. J Am Coll Surg 1999; 188: 304-309.
  • 12
    Abdalla EK, Barnett CC, Doherty D, Curley SA, Vauthey JN. Extended hepatectomy in patients with hepatobiliary malignancies with and without preoperative portal vein embolization. Arch Surg 2002; 137: 675-680.
  • 13
    Ribero D, Abdalla EK, Madoff DC, Donadon M, Loyer EM, Vauthey JN. Portal vein embolization before major hepatectomy and its effects on regeneration, resectability and outcome. Br J Surg 2007; 94: 1386-1394.
  • 14
    Kiuchi T, Kasahara M, Uryuhara K, Inomata Y, Uemoto S, Asonuma K, et al. Impact of graft size mismatching on graft prognosis in liver transplantation from living donors. Transplantation 1999; 67: 321-327.
  • 15
    Fan ST, Lo CM, Liu CL, Yong BH, Wong J. Determinants of hospital mortality of adult recipients of right lobe live donor liver transplantation. Ann Surg 2003; 238: 864-869.
  • 16
    Marcos A. Right lobe living donor liver transplantation: a review. Liver Transpl 2000; 6: 3-20.
  • 17
    Brown RS Jr. Live donors in liver transplantation. Gastroenterology 2008; 134: 1802-1813.
  • 18
    Wang GL, Shi X, Salisbury E, Sun Y, Albrecht JH, Smith RG, et al. Growth hormone corrects proliferation and transcription of phosphoenolpyruvate carboxykinase in livers of old mice via elimination of CCAAT/enhancer-binding protein alpha-Brm complex. J Biol Chem 2007; 282: 1468-1478.
  • 19
    Iakova P, Awad SS, Timchenko NA. Aging reduces proliferative capacities of liver by switching pathways of C/EBPalpha growth arrest. Cell 2003; 113: 495-506.
  • 20
    Jin J, Wang GL, Shi X, Darlington GJ, Timchenko NA. The age-associated decline of glycogen synthase kinase 3beta plays a critical role in the inhibition of liver regeneration. Mol Cell Biol 2009; 29: 3867-3880.
  • 21
    Krupczak-Hollis K, Wang X, Dennewitz MB, Costa RH. Growth hormone stimulates proliferation of old-aged regenerating liver through forkhead box m1b. HEPATOLOGY 2003; 38: 1552-1562.
  • 22
    Ikegami T, Nishizaki T, Yanaga K, Shimada M, Kishikawa K, Nomoto K, et al. The impact of donor age on living donor liver transplantation. Transplantation 2000; 70: 1703-1707.
  • 23
    Zaman MB, Leonard MO, Ryan EJ, Nolan NP, Hoti E, Maguire D, et al. Lower expression of Nrf2 mRNA in older donor livers: a possible contributor to increased ischemia-reperfusion injury? Transplantation 2007; 84: 1272-1278.
  • 24
    Howell TH. Organ weights in nonagenarians. J Am Geriatr Soc 1978; 26: 385-390.
  • 25
    Woodhouse KW, Wynne HA. Age-related changes in liver size and hepatic blood flow. The influence on drug metabolism in the elderly. Clin Pharmacokinet 1988; 15: 287-294.
  • 26
    Wakabayashi H, Nishiyama Y, Ushiyama T, Maeba T, Maeta H. Evaluation of the effect of age on functioning hepatocyte mass and liver blood flow using liver scintigraphy in preoperative estimations for surgical patients: comparison with CT volumetry. J Surg Res 2002; 106: 246-253.
  • 27
    Zoli M, Magalotti D, Bianchi G, Gueli C, Orlandini C, Grimaldi M, et al. Total and functional hepatic blood flow decrease in parallel with ageing. Age Ageing 1999; 28: 29-33.
  • 28
    Warren A, Bertolino P, Cogger VC, McLean AJ, Fraser R, Le Couteur DG. Hepatic pseudocapillarization in aged mice. Exp Gerontol 2005; 40: 807-812.
  • 29
    Ito Y, Sorensen KK, Bethea NW, Svistounov D, McCuskey MK, Smedsrod BH, et al. Age-related changes in the hepatic microcirculation in mice. Exp Gerontol 2007; 42: 789-797.
  • 30
    Kenichi K. Aging and the liver. In: Popper H, Schaffner F, eds. Progressive Liver Disease. Philadelphia: W.B. Saunders; 1990: 603-623.
  • 31
    Corsonello A, Pedone C, Incalzi RA. Age-related pharmacokinetic and pharmacodynamic changes and related risk of adverse drug reactions. Curr Med Chem 2010; 17: 571-584.
  • 32
    Le Couteur DG, Rivory LP, Pond SM. The effects of aging and nutritional state on hypoxia-reoxygenation injury in the perfused rat liver. Transplantation 1994; 58: 531-536.
  • 33
    Selzner M, Selzner N, Jochum W, Graf R, Clavien PA. Increased ischemic injury in old mouse liver: an ATP-dependent mechanism. Liver Transpl 2007; 13: 382-390.
  • 34
    Clavien PA, Selzner M, Rudiger HA, Graf R, Kadry Z, Rousson V, et al. A prospective randomized study in 100 consecutive patients undergoing major liver resection with versus without ischemic preconditioning. Ann Surg 2003; 238: 843-850.
  • 35
    Schwandner O, Schiedeck TH, Bruch HP. Advanced age--indication or contraindication for laparoscopic colorectal surgery? Dis Colon Rectum 1999; 42: 356-362.
  • 36
    Ragab AA, Fye MA, Bohlman HH. Surgery of the lumbar spine for spinal stenosis in 118 patients 70 years of age or older. Spine (Phila Pa 1976) 2003; 28: 348-353.
  • 37
    Bittner R, Butters M, Ulrich M, Uppenbrink S, Beger HG. Total gastrectomy. Updated operative mortality and long-term survival with particular reference to patients older than 70 years of age. Ann Surg 1996; 224: 37-42.
  • 38
    Petrowsky H, Clavien PA. Should we deny surgery for malignant hepato-pancreatico-biliary tumors to elderly patients? World J Surg 2005; 29: 1093-1100.
  • 39
    Fong Y, Blumgart LH, Fortner JG, Brennan MF. Pancreatic or liver resection for malignancy is safe and effective for the elderly. Ann Surg 1995; 222: 426-434.
  • 40
    Yersiz H, Renz JF, Farmer DG, Hisatake GM, McDiarmid SV, Busuttil RW. One hundred in situ split-liver transplantations: a single-center experience. Ann Surg 2003; 238: 496-505.
  • 41
    Behrns KE, Tsiotos GG, DeSouza NF, Krishna MK, Ludwig J, Nagorney DM. Hepatic steatosis as a potential risk factor for major hepatic resection. J Gastrointest Surg 1998; 2: 292-298.
  • 42
    Kooby DA, Fong Y, Suriawinata A, Gonen M, Allen PJ, Klimstra DS, et al. Impact of steatosis on perioperative outcome following hepatic resection. J Gastrointest Surg 2003; 7: 1034-1044.
  • 43
    McCormack L, Petrowsky H, Jochum W, Furrer K, Clavien PA. Hepatic steatosis is a risk factor for postoperative complications after major hepatectomy: a matched case-control study. Ann Surg 2007; 245: 923-930.
  • 44
    Marsman WA, Wiesner RH, Rodriguez L, Batts KP, Porayko MK, Hay JE, et al. Use of fatty donor liver is associated with diminished early patient and graft survival. Transplantation 1996; 62: 1246-1251.
  • 45
    Garcia Urena MA, Colina Ruiz-Delgado F, Moreno Gonzalez E, Jimenez Romero C, Garcia Garcia I, Loinzaz Segurola C, et al. Hepatic steatosis in liver transplant donors: common feature of donor population? World J Surg 1998; 22: 837-844.
  • 46
    Hayashi M, Fujii K, Kiuchi T, Uryuhara K, Kasahara M, Takatsuki M, et al. Effects of fatty infiltration of the graft on the outcome of living-related liver transplantation. Transplant Proc 1999; 31: 403.
  • 47
    Verran D, Kusyk T, Painter D, Fisher J, Koorey D, Strasser S, et al. Clinical experience gained from the use of 120 steatotic donor livers for orthotopic liver transplantation. Liver Transpl 2003; 9: 500-505.
  • 48
    Briceno J, Ciria R, Pleguezuelo M, de la Mata M, Muntane J, Naranjo A, et al. Impact of donor graft steatosis on overall outcome and viral recurrence after liver transplantation for hepatitis C virus cirrhosis. Liver Transpl 2009; 15: 37-48.
  • 49
    Fishbein TM, Fiel MI, Emre S, Cubukcu O, Guy SR, Schwartz ME, et al. Use of livers with microvesicular fat safely expands the donor pool. Transplantation 1997; 64: 248-251.
  • 50
    Jarnagin WR, Gonen M, Fong Y, DeMatteo RP, Ben-Porat L, Little S, et al. Improvement in perioperative outcome after hepatic resection: analysis of 1,803 consecutive cases over the past decade. Ann Surg 2002; 236: 397-406.
  • 51
    Soejima Y, Shimada M, Suehiro T, Kishikawa K, Yoshizumi T, Hashimoto K, et al. Use of steatotic graft in living-donor liver transplantation. Transplantation 2003; 76: 344-348.
  • 52
    Cho JY, Suh KS, Kwon CH, Yi NJ, Lee KU. Mild hepatic steatosis is not a major risk factor for hepatectomy and regenerative power is not impaired. Surgery 2006; 139: 508-515.
  • 53
    Angele MK, Rentsch M, Hartl WH, Wittmann B, Graeb C, Jauch KW, et al. Effect of graft steatosis on liver function and organ survival after liver transplantation. Am J Surg 2008; 195: 214-220.
  • 54
    El-Badry AM, Graf R, Clavien PA. Omega 3--Omega 6: What is right for the liver? J Hepatol 2007; 47: 718-725.
  • 55
    Todo S, Demetris AJ, Makowka L, Teperman L, Podesta L, Shaver T, et al. Primary nonfunction of hepatic allografts with preexisting fatty infiltration. Transplantation 1989; 47: 903-905.
  • 56
    Vuppalanchi R, Unalp A, Van Natta ML, Cummings OW, Sandrasegaran KE, Hameed T, et al. Effects of liver biopsy sample length and number of readings on sampling variability in nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2009; 7: 481-486.
  • 57
    Karcaaltincaba M, Akhan O. Imaging of hepatic steatosis and fatty sparing. Eur J Radiol 2007; 61: 33-43.
  • 58
    DiDonato D, Brasaemle DL. Fixation methods for the study of lipid droplets by immunofluorescence microscopy. J Histochem Cytochem 2003; 51: 773-780.
  • 59
    El-Badry AM, Breitenstein S, Jochum W, Washington K, Paradis V, Rubbia-Brandt L, et al. Assessment of hepatic steatosis by expert pathologists: the end of a gold standard. Ann Surg 2010; 250: 691-697.
  • 60
    El-Badry AM, Moritz W, Contaldo C, Tian Y, Graf R, Clavien PA. Prevention of reperfusion injury and microcirculatory failure in macrosteatotic mouse liver by omega-3 fatty acids. HEPATOLOGY 2007; 45: 855-863.
  • 61
    Iwasaki W, Kume M, Kudo K, Uchinami H, Kikuchi I, Nakagawa Y, et al. Changes in the fatty acid composition of the liver with the administration of N-3 polyunsaturated fatty acids and the effects on warm ischemia/reperfusion injury in the rat liver. Shock 2010; 33: 306-314.
  • 62
    Capanni M, Calella F, Biagini MR, Genise S, Raimondi L, Bedogni G, et al. Prolonged n-3 polyunsaturated fatty acid supplementation ameliorates hepatic steatosis in patients with non-alcoholic fatty liver disease: a pilot study. Aliment Pharmacol Ther 2006; 23: 1143-1151.
  • 63
    Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 2008; 371: 1007-1016.
  • 64
    Hind D, Tappenden P, Tumur I, Eggington S, Sutcliffe P, Ryan A. The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation. Health Technol Assess 2008; 12: iii-ix, xi-162.
  • 65
    Choti MA, Sitzmann JV, Tiburi MF, Sumetchotimetha W, Rangsin R, Schulick RD, et al. Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg 2002; 235: 759-766.
  • 66
    Vauthey JN, Pawlik TM, Ribero D, Wu TT, Zorzi D, Hoff PM, et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 2006; 24: 2065-2072.
  • 67
    Rubbia-Brandt L, Audard V, Sartoretti P, Roth AD, Brezault C, Le Charpentier M, et al. Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol 2004; 15: 460-466.
  • 68
    Miyake K, Hayakawa K, Nishino M, Morimoto T, Mukaihara S. Effects of oral 5-fluorouracil drugs on hepatic fat content in patients with colon cancer. Acad Radiol 2005; 12: 722-727.
  • 69
    Pessayre D, Berson A, Fromenty B, Mansouri A. Mitochondria in steatohepatitis. Semin Liver Dis 2001; 21: 57-69.
  • 70
    Laurent A, Nicco C, Chereau C, Goulvestre C, Alexandre J, Alves A, et al. Controlling tumor growth by modulating endogenous production of reactive oxygen species. Cancer Res 2005; 65: 948-956.
  • 71
    Falcone A, Ricci S, Brunetti I, Pfanner E, Allegrini G, Barbara C, et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol 2007; 25: 1670-1676.
  • 72
    Brouquet A, Benoist S, Julie C, Penna C, Beauchet A, Rougier P, et al. Risk factors for chemotherapy-associated liver injuries: A multivariate analysis of a group of 146 patients with colorectal metastases. Surgery 2009; 145: 362-371.
  • 73
    Aloia T, Sebagh M, Plasse M, Karam V, Levi F, Giacchetti S, et al. Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases. J Clin Oncol 2006; 24: 4983-4990.
  • 74
    Nakano H, Oussoultzoglou E, Rosso E, Casnedi S, Chenard-Neu MP, Dufour P, et al. Sinusoidal injury increases morbidity after major hepatectomy in patients with colorectal liver metastases receiving preoperative chemotherapy. Ann Surg 2008; 247: 118-124.
  • 75
    Selzner N, Pestalozzi BC, Kadry Z, Selzner M, Wildermuth S, Clavien PA. Downstaging colorectal liver metastases by concomitant unilateral portal vein ligation and selective intra-arterial chemotherapy. Br J Surg 2006; 93: 587-592.
  • 76
    Aussilhou B, Dokmak S, Faivre S, Paradis V, Vilgrain V, Belghiti J. Preoperative liver hypertrophy induced by portal flow occlusion before major hepatic resection for colorectal metastases can be impaired by bevacizumab. Ann Surg Oncol 2009; 16: 1553-1559.
  • 77
    Tanaka K, Kumamoto T, Matsuyama R, Takeda K, Nagano Y, Endo I. Influence of chemotherapy on liver regeneration induced by portal vein embolization or first hepatectomy of a staged procedure for colorectal liver metastases. J Gastrointest Surg 2010; 14: 359-368.
  • 78
    Tian Y, Rudiger HA, Jochum W, Clavien PA. Comparison of arterialized and nonarterialized orthotopic liver transplantation in mice: prowess or relevant model? Transplantation 2002; 74: 1242-1246.
  • 79
    Tian Y, Graf R, Jochum W, Clavien PA. Arterialized partial orthotopic liver transplantation in the mouse: a new model and evaluation of the critical liver mass. Liver Transpl 2003; 9: 789-795.
  • 80
    Longo CR, Patel VI, Shrikhande GV, Scali ST, Csizmadia E, Daniel S, et al. A20 protects mice from lethal radical hepatectomy by promoting hepatocyte proliferation via a p21waf1-dependent mechanism. HEPATOLOGY 2005; 42: 156-164.
  • 81
    Cataldegirmen G, Zeng S, Feirt N, Ippagunta N, Dun H, Qu W, et al. RAGE limits regeneration after massive liver injury by coordinated suppression of TNF-alpha and NF-kappaB. J Exp Med 2005; 201: 473-484.
  • 82
    Jin X, Zhang Z, Beer-Stolz D, Zimmers TA, Koniaris LG. Interleukin-6 inhibits oxidative injury and necrosis after extreme liver resection. HEPATOLOGY 2007; 46: 802-812.
  • 83
    Taub R. Liver regeneration: from myth to mechanism. Nat Rev Mol Cell Biol 2004; 5: 836-847.
  • 84
    Fausto N, Campbell JS, Riehle KJ. Liver regeneration. Hepatology 2006; 43: S45-S53.
  • 85
    Cornell RP, Liljequist BL, Bartizal KF. Depressed liver regeneration after partial hepatectomy of germ-free, athymic and lipopolysaccharide-resistant mice. HEPATOLOGY 1990; 11: 916-922.
  • 86
    Cressman DE, Greenbaum LE, DeAngelis RA, Ciliberto G, Furth EE, Poli V, et al. Liver failure and defective hepatocyte regeneration in interleukin-6-deficient mice. Science 1996; 274: 1379-1383.
  • 87
    Yamada Y, Kirillova I, Peschon JJ, Fausto N. Initiation of liver growth by tumor necrosis factor: deficient liver regeneration in mice lacking type I tumor necrosis factor receptor. Proc Natl Acad Sci USA 1997; 94: 1441-1446.
  • 88
    Strey CW, Markiewski M, Mastellos D, Tudoran R, Spruce LA, Greenbaum LE, et al. The proinflammatory mediators C3a and C5a are essential for liver regeneration. J Exp Med 2003; 198: 913-923.
  • 89
    Tian Y, Jochum W, Georgiev P, Moritz W, Graf R, Clavien PA. Kupffer cell-dependent TNF-alpha signaling mediates injury in the arterialized small-for-size liver transplantation in the mouse. Proc Natl Acad Sci USA 2006; 103: 4598-4603.
  • 90
    Iniguez M, Berasain C, Martinez-Anso E, Bustos M, Fortes P, Pennica D, et al. Cardiotrophin-1 defends the liver against ischemia-reperfusion injury and mediates the protective effect of ischemic preconditioning. J Exp Med 2006; 203: 2809-2815.
  • 91
    Jin X, Zimmers TA, Perez EA, Pierce RH, Zhang Z, Koniaris LG. Paradoxical effects of short- and long-term interleukin-6 exposure on liver injury and repair. HEPATOLOGY 2006; 43: 474-484.
  • 92
    He S, Atkinson C, Qiao F, Cianflone K, Chen X, Tomlinson S. A complement-dependent balance between hepatic ischemia/reperfusion injury and liver regeneration in mice. J Clin Invest 2009; 119: 2304-2316.
  • 93
    Lesurtel M, Graf R, Aleil B, Walther DJ, Tian Y, Jochum W, et al. Platelet-derived serotonin mediates liver regeneration. Science 2006; 312: 104-107.
  • 94
    Tian T, Graf R, Mohammad El-Badry A, Lesurtel M, Furrer K, Moritz W, et al. Activation of serotonin receptor-2B rescues small-for-size liver graft failure in mice. HEPATOLOGY 2010. In press.
  • 95
    Myronovych A, Murata S, Chiba M, Matsuo R, Ikeda O, Watanabe M, et al. Role of platelets on liver regeneration after 90% hepatectomy in mice. J Hepatol 2008; 49: 363-372.
  • 96
    Khandoga A, Hanschen M, Kessler JS, Krombach F. CD4+ T cells contribute to postischemic liver injury in mice by interacting with sinusoidal endothelium and platelets. HEPATOLOGY 2006; 43: 306-315.
  • 97
    Sindram D, Porte RJ, Hoffman MR, Bentley RC, Clavien PA. Platelets induce sinusoidal endothelial cell apoptosis upon reperfusion of the cold ischemic rat liver. Gastroenterology 2000; 118: 183-191.
  • 98
    Nocito A, Georgiev P, Dahm F, Jochum W, Bader M, Graf R, et al. Platelets and platelet-derived serotonin promote tissue repair after normothermic hepatic ischemia in mice. HEPATOLOGY 2007; 45: 369-376.
  • 99
    Boillot O, Delafosse B, Mechet I, Boucaud C, Pouyet M. Small-for-size partial liver graft in an adult recipient; a new transplant technique. Lancet 2002; 359: 406-407.
  • 100
    Umeda Y, Yagi T, Sadamori H, Matsukawa H, Matsuda H, Shinoura S, et al. Effects of prophylactic splenic artery modulation on portal overperfusion and liver regeneration in small-for-size graft. Transplantation 2008; 86: 673-680.
  • 101
    Sugimoto H, Kaneko T, Hirota M, Nagasaka T, Kobayashi T, Inoue S, et al. Critical progressive small-graft injury caused by intrasinusoidal pressure elevation following living donor liver transplantation. Transplant Proc 2004; 36: 2750-2756.
  • 102
    Kelly DM, Demetris AJ, Fung JJ, Marcos A, Zhu Y, Subbotin V, et al. Porcine partial liver transplantation: a novel model of the “small-for-size” liver graft. Liver Transpl 2004; 10: 253-263.
  • 103
    Troisi R, Ricciardi S, Smeets P, Petrovic M, Van Maele G, Colle I, et al. Effects of hemi-portocaval shunts for inflow modulation on the outcome of small-for-size grafts in living donor liver transplantation. Am J Transplant 2005; 5: 1397-1404.
  • 104
    Lautt WW. Mechanism and role of intrinsic regulation of hepatic arterial blood flow: hepatic arterial buffer response. Am J Physiol 1985; 249: G549-G556.
  • 105
    Smyrniotis V, Kostopanagiotou G, Kondi A, Gamaletsos E, Theodoraki K, Kehagias D, et al. Hemodynamic interaction between portal vein and hepatic artery flow in small-for-size split liver transplantation. Transpl Int 2002; 15: 355-360.
  • 106
    Marcos A, Olzinski AT, Ham JM, Fisher RA, Posner MP. The interrelationship between portal and arterial blood flow after adult to adult living donor liver transplantation. Transplantation 2000; 70: 1697-1703.
  • 107
    Demetris AJ, Kelly DM, Eghtesad B, Fontes P, Wallis Marsh J, Tom K, et al. Pathophysiologic observations and histopathologic recognition of the portal hyperperfusion or small-for-size syndrome. Am J Surg Pathol 2006; 30: 986-993.
  • 108
    Takada Y, Ueda M, Ishikawa Y, Fujimoto Y, Miyauchi H, Ogura Y, et al. End-to-side portocaval shunting for a small-for-size graft in living donor liver transplantation. Liver Transpl 2004; 10: 807-810.
  • 109
    Taniguchi M, Shimamura T, Suzuki T, Yamashita K, Oura T, Watanabe M, et al. Transient portacaval shunt for a small-for-size graft in living donor liver transplantation. Liver Transpl 2007; 13: 932-934.
  • 110
    Shimada M, Ijichi H, Yonemura Y, Harada N, Shiotani S, Ninomiya M, et al. The impact of splenectomy or splenic artery ligation on the outcome of a living donor adult liver transplantation using a left lobe graft. Hepatogastroenterology 2004; 51: 625-629.
  • 111
    Humar A, Beissel J, Crotteau S, Cohen M, Lake J, Payne WD. Delayed splenic artery occlusion for treatment of established small-for-size syndrome after partial liver transplantation. Liver Transpl 2009; 15: 163-168.
  • 112
    Troisi R, Cammu G, Militerno G, De Baerdemaeker L, Decruyenaere J, Hoste E, et al. Modulation of portal graft inflow: a necessity in adult living-donor liver transplantation? Ann Surg 2003; 237: 429-436.
  • 113
    Nishizaki T, Ikegami T, Hiroshige S, Hashimoto K, Uchiyama H, Yoshizumi T, et al. Small graft for living donor liver transplantation. Ann Surg 2001; 233: 575-580.
  • 114
    Chan SC, Lo CM, Ng KK, Ng IO, Yong BH, Fan ST. Portal inflow and pressure changes in right liver living donor liver transplantation including the middle hepatic vein. Liver Transpl 2010; doi:10.1002/lt.22034.
  • 115
    Makuuchi M, Thai BL, Takayasu K, Takayama T, Kosuge T, Gunven P, et al. Preoperative portal embolization to increase safety of major hepatectomy for hilar bile duct carcinoma: a preliminary report. Surgery 1990; 107: 521-527.
  • 116
    Imamura H, Shimada R, Kubota M, Matsuyama Y, Nakayama A, Miyagawa S, et al. Preoperative portal vein embolization: an audit of 84 patients. HEPATOLOGY 1999; 29: 1099-1105.
  • 117
    Nagino M, Kamiya J, Nishio H, Ebata T, Arai T, Nimura Y. Two hundred forty consecutive portal vein embolizations before extended hepatectomy for biliary cancer: surgical outcome and long-term follow-up. Ann Surg 2006; 243: 364-372.
  • 118
    Abdalla EK, Hicks ME, Vauthey JN. Portal vein embolization: rationale, technique and future prospects. Br J Surg 2001; 88: 165-175.
  • 119
    Adam R, Delvart V, Pascal G, Valeanu A, Castaing D, Azoulay D, et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg 2004; 240: 644-657.
  • 120
    Petrowsky H, McCormack L, Trujillo M, Selzner M, Jochum W, Clavien PA. A prospective, randomized, controlled trial comparing intermittent portal triad clamping versus ischemic preconditioning with continuous clamping for major liver resection. Ann Surg 2006; 244: 921-928.
  • 121
    Welsh FK, Tilney HS, Tekkis PP, John TG, Rees M. Safe liver resection following chemotherapy for colorectal metastases is a matter of timing. Br J Cancer 2007; 96: 1037-1042.
  • 122
    Selzner N, Rudiger H, Graf R, Clavien PA. Protective strategies against ischemic injury of the liver. Gastroenterology 2003; 125: 917-936.
  • 123
    Petrowsky H, Breitenstein S, Slankamenac K, Vetter D, Lehmann K, Heinrich S, et al. Effects of pentoxifylline on liver regeneration: A double-blinded randomized controlled trial in 101 patients undergoing major liver resection. Ann Surg 2010. In press.
  • 124
    Baskin-Bey ES, Washburn K, Feng S, Oltersdorf T, Shapiro D, Huyghe M, et al. Clinical trial of the pan-caspase inhibitor, IDN-6556, in human liver preservation injury. Am J Transplant 2007; 7: 218-225.
  • 125
    Clavien PA, Yadav S, Sindram D, Bentley RC. Protective effects of ischemic preconditioning for liver resection performed under inflow occlusion in humans. Ann Surg 2000; 232: 155-162.
  • 126
    Azoulay D, Del Gaudio M, Andreani P, Ichai P, Sebag M, Adam R, et al. Effects of 10 minutes of ischemic preconditioning of the cadaveric liver on the graft's preservation and function: the ying and the yang. Ann Surg 2005; 242: 133-139.
  • 127
    Rahbari NN, Wente MN, Schemmer P, Diener MK, Hoffmann K, Motschall E, et al. Systematic review and meta-analysis of the effect of portal triad clamping on outcome after hepatic resection. Br J Surg 2008; 95: 424-432.
  • 128
    Smyrniotis V, Theodoraki K, Arkadopoulos N, Fragulidis G, Condi-Pafiti A, Plemenou-Fragou M, et al. Ischemic preconditioning versus intermittent vascular occlusion in liver resections performed under selective vascular exclusion: a prospective randomized study. Am J Surg 2006; 192: 669-674.
  • 129
    Beck-Schimmer B, Breitenstein S, Urech S, De Conno E, Wittlinger M, Puhan M, et al. A randomized controlled trial on pharmacological preconditioning in liver surgery using a volatile anesthetic. Ann Surg 2008; 248: 909-918.
  • 130
    Yue T, Roth Z'graggen B, Blumenthal S, Neff SB, Reyes L, Booy C, et al. Postconditioning with a volatile anaesthetic in alveolar epithelial cells in vitro. Eur Respir J 2008; 31: 118-125.
  • 131
    Kaneda K, Miyamae M, Sugioka S, Okusa C, Inamura Y, Domae N, et al. Sevoflurane enhances ethanol-induced cardiac preconditioning through modulation of protein kinase C, mitochondrial KATP channels, and nitric oxide synthase, in guinea pig hearts. Anesth Analg 2008; 106: 9-16.
  • 132
    Lang JD Jr, Teng X, Chumley P, Crawford JH, Isbell TS, Chacko BK, et al. Inhaled NO accelerates restoration of liver function in adults following orthotopic liver transplantation. J Clin Invest 2007; 117: 2583-2591.
  • 133
    Puder M, Valim C, Meisel JA, Le HD, de Meijer VE, Robinson EM, et al. Parenteral fish oil improves outcomes in patients with parenteral nutrition-associated liver injury. Ann Surg 2009; 250: 395-402.
  • 134
    Khan AZ, Morris-Stiff G, Makuuchi M. Patterns of chemotherapy-induced hepatic injury and their implications for patients undergoing liver resection for colorectal liver metastases. J Hepatobiliary Pancreat Surg 2009; 16: 137-144.